Excelsior Biopharma (6496) — Financial Flexibility Index
Excelsior Biopharma (6496) has a Financial Flexibility Index of -0.03x as of December 2025. Free cash flow of NT$-20.81 Million (operating CF NT$-22.21 Million minus capex NT$1.40 Million) represents 0% of total liabilities (NT$679.78 Million). Check Excelsior Biopharma investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Excelsior Biopharma Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for Excelsior Biopharma across 9 annual periods. For the full cash flow conversion analysis, see Excelsior Biopharma (6496) cash flow conversion.
Annual Financial Flexibility Index for Excelsior Biopharma (2017–2025)
Year-by-year free cash flow to debt coverage for Excelsior Biopharma. Explore 6496 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.15x | NT$-101.78 Million | NT$-138.72 Million | NT$679.78 Million | ▼ -155.8% |
| 2024 | 0.27x | NT$157.35 Million | NT$-99.80 Million | NT$586.89 Million | ▲ +227.9% |
| 2023 | -0.21x | NT$-99.09 Million | NT$-134.75 Million | NT$472.87 Million | ▼ -901.5% |
| 2022 | 0.03x | NT$13.27 Million | NT$5.49 Million | NT$507.53 Million | ▼ -72.9% |
| 2021 | 0.10x | NT$58.70 Million | NT$55.82 Million | NT$608.90 Million | ▼ -88.8% |
| 2020 | 0.86x | NT$532.43 Million | NT$520.81 Million | NT$617.15 Million | ▲ +241.0% |
| 2019 | -0.61x | NT$-149.36 Million | NT$-169.74 Million | NT$244.06 Million | ▼ -221.5% |
| 2018 | 0.50x | NT$136.46 Million | NT$126.92 Million | NT$270.88 Million | ▼ -53.5% |
| 2017 | 1.08x | NT$367.57 Million | NT$349.47 Million | NT$339.37 Million | — |